Findings from a phase I study suggest that delivering high concentrations of the 
chemotherapy 5-FU directly to brain tumors via the retroviral vector vocimagene 
amiretrorepvec, or Toca 511, may benefit patients with recurrent high-grade 
glioma. This investigational treatment was well tolerated and induced robust, 
durable responses lasting a median of 3 years.